Intra Cellular Therapies Stock Net Asset
| ITCIDelisted Stock | USD 131.87 0.03 0.02% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Intra Cellular's long-term financial health and intrinsic value.
Intra |
Intra Cellular Therapies Company Net Asset Analysis
Intra Cellular's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Intra Cellular Net Asset | 1.37 B |
Most of Intra Cellular's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intra Cellular Therapies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Intra Cellular Therapies has a Net Asset of 1.37 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Intra Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intra Cellular's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intra Cellular could also be used in its relative valuation, which is a method of valuing Intra Cellular by comparing valuation metrics of similar companies.Intra Cellular is currently under evaluation in net asset category among its peers.
Intra Fundamentals
| Return On Equity | -0.0858 | |||
| Return On Asset | -0.0696 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | (0.15) % | |||
| Current Valuation | 13.06 B | |||
| Shares Outstanding | 106.52 M | |||
| Shares Owned By Insiders | 2.48 % | |||
| Shares Owned By Institutions | 96.40 % | |||
| Number Of Shares Shorted | 2.67 M | |||
| Price To Earning | (6.56) X | |||
| Price To Book | 12.23 X | |||
| Price To Sales | 20.63 X | |||
| Revenue | 680.85 M | |||
| Gross Profit | 387.77 M | |||
| EBITDA | (116.72 M) | |||
| Net Income | (74.68 M) | |||
| Cash And Equivalents | 628.74 M | |||
| Cash Per Share | 6.64 X | |||
| Total Debt | 16.98 M | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 9.81 X | |||
| Book Value Per Share | 10.81 X | |||
| Cash Flow From Operations | (73.18 M) | |||
| Short Ratio | 1.20 X | |||
| Earnings Per Share | (0.73) X | |||
| Target Price | 132.0 | |||
| Number Of Employees | 860 | |||
| Beta | 0.46 | |||
| Market Capitalization | 14.05 B | |||
| Total Asset | 1.37 B | |||
| Retained Earnings | (1.69 B) | |||
| Working Capital | 1.1 B | |||
| Current Asset | 541.82 M | |||
| Current Liabilities | 140.69 M | |||
| Net Asset | 1.37 B |
About Intra Cellular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intra Cellular Therapies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intra Cellular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intra Cellular Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in commodities. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Intra Stock
If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra Cellular's history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |